| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 12 Nov 2026 | S-3 |
| 12 Nov 2026 | S-8 |
| 12 Nov 2026 |
8-K/A: Financial Statements and Exhibits
We have audited the combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. (together, “the Company”), which comprise the combined balance sheets as of December 31, 2025 and 2024, and the related combined stat... |
| 09 Nov 2026 | DEFA14A |
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
The name of the plan is the Lisata Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultan... |
| 19 Oct 2026 | ARS |
| 19 Oct 2026 |
Proxy statement: annual meeting on November 9, 2026
CEO pay $1.1M, down 32% · say-on-pay vote |
| 15 Oct 2026 |
Form 3: Farrow Jeffrey S, Director
Holds 0 shares of No securities are beneficially owned |
| 14 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee |
| 07 Oct 2026 | PRE 14A |
| 02 Oct 2026 | D |
| 28 Sep 2026 |
Form 3: Love Ted W, Director
Holds 19,260 shares of Common Stock |
| 28 Sep 2026 |
Form 3: Lehrer-Graiwer Joshua, President & COO
Holds 21,548 shares of Common Stock |
| 17 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 17, 2026, by and among Lisata Therapeutics, Inc., a Delaware corporation (“Parent”), Mariner Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiar... |
| 26 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
We are pleased to inform you that, in recognition of your contributions to Lisata Therapeutics, Inc. (the “Company”), you are being offered the opportunity to receive a retention bonus (the “Retention Bonus”) on the following terms and c... |
| 28 Jul 2026 | SC TO-T/A |
| 24 Jul 2026 |
8-K: Termination of a Material Definitive Agreement; Other Events
On July 24, 2026, Lisata Therapeutics, Inc. (the “Company”) terminated the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva Labs Inc., a Delaware corporation (“Parent”) and Kuva Acquisition ... |
Loading...